Expression of CD74 in bladder cancer and its suppression in association with cancer proliferation, invasion and angiogenesis in HT-1376 cells

Gai,Jun‑Wei; Wahafu,Wasilijiang; Song,Liming; Ping,Hao; Wang,Mingshuai; Yang,Feiya; Niu,Yinong; Qing,Wei; Xing,Nianzeng

doi:10.3892/ol.2018.8309

Expression of CD74 in bladder cancer and its suppression in association with cancer proliferation, invasion and angiogenesis in HT-1376 cells

Authors:
- Jun‑Wei Gai
- Wasilijiang Wahafu
- Liming Song
- Hao Ping
- Mingshuai Wang
- Feiya Yang
- Yinong Niu
- Wei Qing
- Nianzeng Xing
View Affiliations

Affiliations: Department of Urology, Tianjin First Central Hospital, Tianjin 300191, P.R. China, Department of Urology, Beijing Chao‑Yang Hospital, Beijing 100020, P.R. China, Department of Orthopedics, Xiangyang Central Hospital, Xiangyang, Hubei 441021, P.R. China
Published online on: March 21, 2018 https://doi.org/10.3892/ol.2018.8309
Pages: 7631-7638
Copyright: © Gai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression and potential roles of CD74 in human urothelial cell carcinoma of the bladder (UCB) in vitro and in vivo. CD74 and macrophage migration inhibitory factor (MIF) were located and assayed in normal and UCB samples and cell lines using immunostaining. CD74 was knocked down using CD74 shRNA lentiviral particles in HT‑1376 cells. The proliferative, invasive potential and microvessel density (MVD) of knockdown‑CD74 HT‑1376 cells were analyzed in vitro or in vivo. The expression of CD74 in an additional high grade UCB J82 cell line was also verified in vivo. All experiments were repeated at least 3 times. The majority of muscle‑invasive bladder cancer (MIBC) samples, and only one high grade UCB cell line, HT‑1376, expressed CD74, compared with normal, non‑ muscle‑invasive bladder cancer (NMIBC) samples and other cell lines. The levels of proliferation and invasion were decreased in the CD74 knockdown‑HT‑1376 cells, and western blotting assay indicated that the levels of proteins associated with proliferation, apoptosis and invasion in the cells were affected correspondingly by different treatments in vitro. The tumorigenesis and MVD assays indicated less proliferation and angiogenesis in the knockdown‑HT‑1376 cells compared with the scramble cells. Notably, J82 cells exhibiting no signal of CD74 in vitro presented the expression of CD74 in vivo. The present study revealed the potential roles of CD74 in the proliferation, invasion and angiogenesis of MIBC, and that it may serve as a potential therapeutic target for UCB, but additional studies are required.

View Figures

View References

1	Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S and Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
2	McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B: Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 28:429–440. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
4	Serrano C, Morales R, Suárez C, Núñez I, Valverde C, Rodón J, Humbert J, Padrós O and Carles J: Emerging therapies for urothelial cancer. Cancer Treat Rev. 38:311–317. 2012. View Article : Google Scholar : PubMed/NCBI
5	Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, et al: A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 62:523–533. 2012. View Article : Google Scholar : PubMed/NCBI
6	Meyer-Siegler KL, Leifheit EC and Vera PL: Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer. 4:342004. View Article : Google Scholar : PubMed/NCBI
7	Taylor JA III, Kuchel GA, Hegde P, Voznesensky OS, Claffey K, Tsimikas J, Leng L, Bucala R and Pilbeam C: Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer. 7:1352007. View Article : Google Scholar : PubMed/NCBI
8	Al-Abed Y and VanPatten S: MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem. 3:45–63. 2011. View Article : Google Scholar : PubMed/NCBI
9	Babu SN, Chetal G and Kumar S: Macrophage migration inhibitory factor: A potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev. 13:1737–1744. 2012. View Article : Google Scholar : PubMed/NCBI
10	Calandra T and Roger T: Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol. 3:791–800. 2003. View Article : Google Scholar : PubMed/NCBI
11	Larson DF and Horak K: Macrophage migration inhibitory factor: Controller of systemic inflammation. Crit Care. 10:1382006. View Article : Google Scholar : PubMed/NCBI
12	Becker-Herman S, Arie G, Medvedovsky H, Kerem A and Shachar I: CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell. 16:5061–5069. 2005. View Article : Google Scholar : PubMed/NCBI
13	Borghese F and Clanchy FI: CD74: An emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets. 15:237–251. 2011. View Article : Google Scholar : PubMed/NCBI
14	Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B and Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2635:5046–5059. 2007. View Article : Google Scholar
15	Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, Becker-Herman S, Berrebi A and Shachar I: Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 107:4807–4816. 2006. View Article : Google Scholar : PubMed/NCBI
16	Choi JW, Kim Y, Lee JH and Kim YS: CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder. Int J Urol. 20:251–255. 2013. View Article : Google Scholar : PubMed/NCBI
17	Edge S, Byrd D, Compton C, Fritz A, Greene F and Trotti A: AJCC cancer staging manual. edition 7. New York, NY: Springer; 2010
18	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
19	Association for assessment and accreditation of laboratory animal care international. [Internet]. 2011. AAALAC International rules of accreditation. Section 2.d. [Cited April 2012]. http://www.aaalac.org/accreditation/rules.cfm
20	Offersen BV, Pfeiffer P, Hamilton-Dutoit S and Overgaard J: Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer. 91:1500–1509. 2001. View Article : Google Scholar : PubMed/NCBI
21	Cooke G, Armstrong ME and Donnelly SC: Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. Biofactors. 35:165–168. 2009. View Article : Google Scholar : PubMed/NCBI
22	Conroy H, Mawhinney L and Donnelly SC: Inflammation and cancer: Macrophage migration inhibitory factor (MIF)-the potential missing link. QJM. 103:831–836. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et al: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 13:587–596. 2007. View Article : Google Scholar : PubMed/NCBI
24	Cheng RJ, Deng WG, Niu CB, Li YY and Fu Y: Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int J Gynecol Cancer. 21:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
25	Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, Wang ZH, Shen LS and Cui L: CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World J Gastroenterol. 18:2253–2261. 2012. View Article : Google Scholar : PubMed/NCBI
26	Metodieva G, Nogueira-de-Souza NC, Greenwood C, Al-Janabi K, Leng L, Bucala R and Metodiev MV: CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia. 15:660–668. 2013. View Article : Google Scholar : PubMed/NCBI
27	Matsuura S, Shinmura K, Kamo T, Igarashi H, Maruyama K, Tajima M, Ogawa H, Tanahashi M, Niwa H, Funai K, et al: CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. Oncol Rep. 30:1675–1680. 2013. View Article : Google Scholar : PubMed/NCBI
28	Bifulco C, McDaniel K, Leng L and Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des. 14:3790–3801. 2008. View Article : Google Scholar : PubMed/NCBI
29	Hadler-Olsen E, Winberg JO and Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
30	Khoufache K, Bazin S, Girard K, Guillemette J, Roy MC, Verreault JP, Al-Abed Y, Foster W and Akoum A: Macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo. PLoS One. 7:e372642012. View Article : Google Scholar : PubMed/NCBI
31	Giannice R, Erreni M, Allavena P, Buscaglia M and Tozzi R: Chemokines mRNA expression in relation to the Macrophage migration inhibitory factor (MIF) mRNA and vascular endothelial growth factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: A pilot study. Cytokine. 64:509–515. 2013. View Article : Google Scholar : PubMed/NCBI
32	Cao WG, Morin M, Sengers V, Metz C, Roger T, Maheux R and Akoum A: Tumour necrosis factor-alpha up-regulates macrophage migration inhibitory factor expression in endometrial stromal cells via the nuclear transcription factor NF-kappaB. Hum Reprod. 21:421–428. 2006. View Article : Google Scholar : PubMed/NCBI
33	Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S and Goldenberg DM: CD74: A new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 13:S5556–S5563. 2007. View Article : Google Scholar
34	Berkova Z, Tao RH and Samaniego F: Milatuzumab-a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 19:141–149. 2010. View Article : Google Scholar : PubMed/NCBI
35	Stein R, Smith MR, Chen S, Zalath M and Goldenberg DM: Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res. 15:2808–2817. 2009. View Article : Google Scholar : PubMed/NCBI